Its advantages over traditional low-throughput quantitative methods such as ELISA, Western blotting, and immunohistochemistry include multiplexing, a precise relative and complete quantification of endogenous analytes, no antibody requirement, and an ability to detect unmodified and posttranslationally modified forms of proteins [813]

Its advantages over traditional low-throughput quantitative methods such as ELISA, Western blotting, and immunohistochemistry include multiplexing, a precise relative and complete quantification of endogenous analytes, no antibody requirement, and an ability to detect unmodified and posttranslationally modified forms of proteins [813]. of this article (doi: 10. 1186/s12859-015-0838-z) contains supplementary material, which is accessible to authorized users. == Background == Selected or Multiple reaction monitoring (SRM and MRM) TMI-1 mass spectrometry is the most Rabbit polyclonal to PDK4 widely used MS-based targeted proteomic approach. In contrast to discovery proteomics [16], targeted proteomics strategies entail limiting the number of features monitored and optimizes chromatography, instrument tuning, and acquisition methods to achieve high sensitivity [7]. Its advantages over traditional low-throughput quantitative methods such as ELISA, Western blotting, and immunohistochemistry include multiplexing, a precise relative and complete quantification of endogenous analytes, no antibody requirement, and an ability to detect unmodified and posttranslationally modified forms of proteins [813]. These limitations TMI-1 and opportunities presented by SRM/MRM are well articulated by Shi et al. [14]. As surrogates to protein expression level quantification methods such as mRNA microarray and RNASeq methods fall short of an ability to detect posttranslationally modified proteins, the demand for SRM or MRM-based analytical methods is anticipated to increase [7]. Similar to parallel reaction monitoring (PRM), MRM typically involves monitoring a multiplexed assay of proteotypic peptides. However under conditions that permit high resolution and high mass precision, only a set of preselected transitions are monitored in MRM as opposed to all transitions in PRM [15, 16]. An MRM assay development workflow may be broadly sub-divided into a pre-mass spectrometry purchase phase and a post-acquisition phase. The pre-acquisition phase includes, 1) generation of target protein list, 2) selection of proteotypic peptides and 3) an experimental design step [17]. The post-acquisition phase recently explained by Colangelo et al [7] entails four major steps; 1) peak detection, integration TMI-1 and quantification, 2) data quality assessment, 3) data visualization and exploratory analysis, and 4) fold change/statistical significance analysis. Irrespective of the targeted proteomics approach used, the complexities of press within which monitored proteotypic peptides that represent proteins of interest reside result in the somewhat unpredictable analytical behavior of peptides and transitions. Thus, it is important that experimental and analytical validation is performed to describe peptides and associated transitions as stable, quantifiable, and reproducible representatives of proteins of interest. To standardize and validate quantifiable targeted mass spectrometry-based peptide and protein quantifications, the National Cancer Institute (NCI) National Institutes of Health through the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Development Working Group (ADWG) recently described guidelines, experiments and analytical measures for MRM assay characterization [18]. Extending previously published guidelines and studies [19, 20], the described guidelines ensure some levels of confidence for assayed peptides and proteins in quantitative targeted proteomics studies. Currently available commercial, proprietary tools and open source, vendor-neutral analytical tools intended for post-data purchase processing are extensively explained in Cham et al [21], Brusniak et al [17], Colangelo et al [7] and Mani et al [19]. TMI-1 Though these tools are highly credible in addressing individual analytical difficulties, we found no suitable standalone, platform-independent tool that readily implements the CPTAC ADWGs recommendation for the evaluation of assay performance. However , Skyline [22], described as the most complete open source platform addressing a great deal of the analytical requirements of an MRM assay development protocol, provided a sufficient basis for the development of MRMPlus. Streamlining workflow (Fig. 1) and minimizing error predisposition, MRMPlus takes as input, Skyline derived preprocessed files (Additional file1: Table S1), in addition to user defined metadata files (Additional files2and3: Furniture S2 and S3) to compute analytical and validation measures as recommended and described in the CPTAC ADWG published guidelines (https://assays.cancer.gov/guidance-document/). == Fig. 1 . == MRMPlus Concept/Flow Diagram. Mass spectrometry data are first preprocessed in Skyline and subsequently fed as input to MRMPlus. In addition , MRMPlus takes as inputs, user-defined experiment metadata and a serial dilution information file Although MRMPlus was conceptualized and implemented to compute the performance of assays developed according to guidelines established by the CPTAC Assay Development Working Group, it may also be used for performance calculations intended for targeted assays not explained by the Working Group. == Implementation == We implemented MRMPlus in the platform-independent Java programing language (Fig. 2). For statistical evaluations, we.